People with schizophrenia will soon have a new treatment option after the FDA approved its first new treatment for the mental ...

The conference also served to educate the attendees about UAMS' Odyssey Clinic. Dr. Craig Jones, the clinic's program manager, said it opened July 1 and works with schizophrenia patients 16 years or ...

Despite schizophrenia, the jury rejected the defense's contention that the man was insane at the time of the 2021 attack.

Despite billions of taxpayer dollars spent on mental illness research, Cobenfy was developed by a private biopharmaceutical ...

On Thursday, the U.S. Food and Drug Administration approved COBENFY, an oral medication that marks the first new class of ...

U.S. FDA Approves Bristol Myers Squibb’s COBENFY, a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults ...

Xanomeline and trospium chloride is a first-in-class medication that selectively targets the M1 and M4 receptors without blocking D2 receptors.

A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to ...

Children who are overweight or obese are more likely to develop schizophrenia as adults, according to a recent study. But adults with excess weight seem to have a lower risk of both schizophrenia ...

London: Neurocrine Biosciences said on Thursday it will halt the development of its experimental drug, aimed at improving cognitive function in patients with schizophrenia, after it did not ...

Neurocrine Biosciences’ schizophrenia program pivot has failed. The biotech was unable to replicate the cognition signal it saw in an earlier midphase study, prompting it to stop development of ...

The trial enrolled adults with cognitive impairment associated with schizophrenia. Credit: PeopleImages.com – Yuri A / Shutterstock. Neurocrine Biosciences has reported that its Phase II ERUDITE ...